Personalis
1330 O’Brien Drive
Menlo Park
California
94025
United States
Tel: 1-650-752-1300
Website: http://www.personalis.com/
215 articles about Personalis
-
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
11/7/2022
Personalis, Inc. (Nasdaq: PSNL) today announced that the company will share data resulting from expanded features of its NeXT Platform® at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-12 in Boston, with three abstracts that highlight advanced R&D applications of next-generation sequencing (NGS) in immuno-oncology.
-
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
10/31/2022
Personalis, Inc., a leader in advanced genomics for cancer, announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business.
-
Personalis to Announce Third Quarter 2022 Financial Results
10/19/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022.
-
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
10/4/2022
Personalis, Inc. has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer.
-
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
8/30/2022
Personalis, Inc. announced that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY. About Personalis Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.
-
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
8/17/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics.
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 16, 2022
8/16/2022
Personalis, Inc. announced that, effective on August 15, 2022, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of its common stock and restricted stock units covering an aggregate of 70,000 shares of its common stock to two new employees under Personalis’ 2020 Inducement Plan.
-
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
8/15/2022
Personalis, Inc. has announced a collaboration with BC Cancer to deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal and pancreatic cancers.
-
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
8/4/2022
Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022.
-
Personalis Reports Second Quarter 2022 Financial Results
8/3/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022.
-
Personalis to Announce Second Quarter 2022 Financial Results
7/20/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022.
-
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
7/12/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.
-
GenomOncology Selected by Personalis to Support MRD and SNV Analysis for NeXT Personal™ Assay
7/12/2022
GenomOncology announced that the GenomOncology Pathology Workbench has been selected by Personalis to support its NeXT Personal assay for molecular residual disease detection.
-
Personalis Reports First Quarter 2022 Financial Results
5/4/2022
Personalis, Inc., a leader in advanced genomics for precision oncology, reported financial results for the first quarter ended March 31, 2022.
-
Personalis to Present at Upcoming Investor Conferences - Apr 28, 2022
4/28/2022
Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will present at the following investor conferences.
-
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
4/21/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales.
-
Personalis to Announce First Quarter 2022 Financial Results
4/20/2022
Personalis, Inc., a leader in advanced genomics for cancer, announced that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022.
-
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
4/12/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, "A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity," in Nature Communications.
-
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
4/12/2022
Personalis, Inc. announced the issuance of a key US Patent related to its industry-leading minimal residual disease (MRD) and recurrence platform, NeXT Personal.
-
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022
4/11/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced its co-authorship of a study with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to be presented during the American Association for Cancer Research Annual Meeting 2022 from April 8-13, 2022.